Annexon Biosciences Reports Third Quarter GAAP EPS of -$0.25 and Updates Clinical Trial Progress
Annexon Biosciences (ANNX) reported its third-quarter financial results, posting a GAAP earnings per share (EPS) loss of $0.25. As of September 30, 2026, the company maintained a strong liquidity position with $213 million in cash, cash equivalents, and short-term investments, which management expects will provide an operational runway extending into 2028. On the clinical front, the company is advancing its Phase III ARCHER II trial for Vonaprument in treating geographic atrophy. Annexon plans to file a Biologics License Application (BLA) for tanruprubart in Q4 and has added a month-24 dual primary endpoint to the ARCHER II study to further evaluate patient function preservation.
Tickers: $ANNX
Topics: biotechnology cash runway clinical trials earnings report
Read the full article at Seeking Alpha
Part of the story Sensei Biotherapeutics Reports Q3 GAAP EPS of -$0.79, Slightly Missing Estimates (8 articles)